CCA
CEROW

Castle Creek Arbitrage’s CERo Therapeutics Warrants CEROW Stock Holding History

Castle Creek Arbitrage’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200,000
Closed -$14.3K – 69
2023
Q3 		$14.3K Hold
200,000
– – ﹤0.01% 152
2023
Q2 		$12.2K Hold
200,000
– – ﹤0.01% 256
2023
Q1 		$8K Hold
200,000
– – ﹤0.01% 373
2022
Q4 		$8.62K Buy
+200,000
New +$10.5K ﹤0.01% 392

Other funds holding CEROW

SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Castle Creek Arbitrage's CEROW Position: Q4 2023 in Review

Castle Creek Arbitrage sold out of CERo Therapeutics Warrants (CEROW) in Q4 2023, closing a stake of 200,000 shares — an estimated $14.3K sold.

Castle Creek Arbitrage first reported a position in CEROW in Q4 2022 and held it in 4 quarters. The position peaked at $14.3K in Q3 2023. 40 funds tracked by Wall St. Rank hold CEROW as of Q4 2023.

  • Castle Creek Arbitrage reported no remaining CERo Therapeutics Warrants position as of Q4 2023 after selling out during the quarter.
  • Castle Creek Arbitrage sold 200,000 CERo Therapeutics Warrants shares in Q4 2023, an estimated $14.3K.
  • Castle Creek Arbitrage first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 4 quarters.
  • Castle Creek Arbitrage's CERo Therapeutics Warrants position peaked at $14.3K in Q3 2023.
  • 40 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2023.

Based on Castle Creek Arbitrage's 13F filing for Q4 2023.